ArticleJournal for immunotherapy of cancer2021

Pembrolizumab with low-dose carboplatin for recurrent platinum-resistant ovarian, fallopian tube, and primary peritoneal cancer: survival and immune correlates.

John B Liao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.